心脏骤停复苏后目标温度管理期间持续与间断神经肌肉阻滞的随机双盲双模拟临床试验
该随机双盲双模拟临床试验纳入63例心脏骤停复苏后接受目标温度管理的患者,随机分为持续输注罗库溴铵组(32例)与持续输注生理盐水并按需推注罗库溴铵组(31例)。主要终点寒战发作在按需推注组为94%,持续输注组为25%(p<0.01)。持续输注组咪达唑仑(4.3±0.8mg/kg vs 5.1±0.9mg/kg)和芬太尼(62±14μg/kg vs 71±7μg/kg)累积剂量更低,罗库溴铵累积剂量更高(7.8±1.8mg/kg vs 2.3±1.6mg/kg),苏醒更早(2[IQR 2;3]天 vs 4[IQR 2;7.5]天)且ICU停留更短(6[IQR 3;5.9]天 vs 10[IQR 5;15]天)。12个月生存和生活质量无显著差异。
要点
- 持续输注罗库溴铵组寒战发作25%,按需推注组94%(p<0.01)。
- 持续输注组咪达唑仑累积剂量4.3±0.8mg/kg低于按需推注组5.1±0.9mg/kg(p<0.01)。
- 持续输注组芬太尼累积剂量62±14μg/kg低于按需推注组71±7μg/kg(p<0.01)。
- 持续输注组苏醒时间2[IQR 2;3]天早于按需推注组4[IQR 2;7.5]天(p=0.04),ICU停留6[IQR 3;5.9]天短于10[IQR 5;15]天(p=0.03)。
- 12个月生存和生活质量无显著差异。
适用人群与场景
- 心脏骤停复苏后接受目标温度管理的患者。
处置流程与药物剂量
- 持续神经肌肉阻滞组持续输注罗库溴铵。
- 按需神经肌肉阻滞组持续输注生理盐水,并根据需要推注罗库溴铵。
研究设计与关键结果
- 随机双盲双模拟临床试验,纳入63例患者(持续神经肌肉阻滞组32例,按需推注组31例),基线特征无显著差异。
- 主要终点寒战发作:按需推注组94% vs 持续神经肌肉阻滞组25%(p<0.01)。
- 持续神经肌肉阻滞组咪达唑仑累积剂量4.3±0.8mg/kg vs 按需推注组5.1±0.9mg/kg(p<0.01),芬太尼62±14μg/kg vs 71±7μg/kg(p<0.01),罗库溴铵7.8±1.8mg/kg vs 2.3±1.6mg/kg(p<0.01)。
- 持续神经肌肉阻滞组苏醒时间2[IQR 2;3]天 vs 按需推注组4[IQR 2;7.5]天(p=0.04),ICU停留时间6[IQR 3;5.9]天 vs 10[IQR 5;15]天(p=0.03)。
- 12个月生存和生活质量无显著差异,降温速率和达目标温度时间无差异。
证据类型、等级与局限
- 证据类型:随机双盲双模拟临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为心脏骤停复苏后首日持续神经肌肉阻滞可减少寒战、降低咪达唑仑和芬太尼需求、缩短苏醒时间和ICU停留时间,但12个月生存无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM OF THE STUDY: Current guidelines recommend targeted temperature management to improve neurological outcome after cardiac arrest. Evidence regarding an ideal sedative/analgesic regimen including skeletal muscle paralysis is limited.
METHODS: Patients were randomized to either a continuous administration of rocuronium (continuous-NMB-group) or to a continuous administration of saline supplemented by rocuronium bolus administration if demanded (bolus-NMB-group). The primary outcome was the number of shivering episodes. Secondary outcomes included survival and neurological status one year after cardiac arrest, time to awakening, length of stay as well as required cumulative dose of rocuronium, midazolam and fentanyl.
RESULTS: Sixty-three patients (32 continuous-NMB-group; 31 bolus-NMB-group) were enrolled. Differences in baseline characteristics were not significant. Shivering episodes were detected in 94% of the patients in the bolus-NMB-group compared to 25% of the patients receiving continuous rocuronium infusion (p<0.01). The continuous-NMB-group received significant lower doses of midazolam (4.3±0.8mg/kg vs. 5.1±0.9mg/kg, p<0.01) and fentanyl (62±14μg/kg vs. 71±7μg/kg, p<0.01), but higher cumulative doses of rocuronium (7.8±1.8mg/kg vs. 2.3±1.6mg/kg, p<0.01). Earlier awakening (2 [IQR 2;3] vs. 4 [IQR 2;7.5] days, p=0.04) and decreased length of stay at the ICU (6 [IQR 3;5.9] vs. 10 [IQR 5;15] days, p=0.03) were observed in the continuous-NMB-group. There were no significant differences in survival and quality of life 12 months after cardiac arrest.
CONCLUSIONS: Continuous neuromuscular blockade during the first day after resuscitation reduced shivering, midazolam and fentanyl requirement, time to awakening and discharge from intensive care unit. There were no differences in overall survival, cooling rate and time to target temperature.
参考来源
- Stöckl M, Testori C, Sterz F, et al. Continuous versus intermittent neuromuscular blockade in patients during targeted temperature management after resuscitation from cardiac arrest-A randomized, double blinded, double dummy, clinical trial. Resuscitation. 2017. PMID: 28860012. doi:10.1016/j.resuscitation.2017.08.238
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。